OHR Pharmaceutical Inc.

Ohr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11

Download PDF

NEW YORK, May 09, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its second fiscal quarter ended March 31, 2017 after the market close on Thursday, May 11, 2017.  The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.

Conference Call & Webcast  
Thursday, May 11, 2017 at 5:00pm Eastern Time
Domestic: 877-407-0789
International: 201-689-8562
Conference ID: 13661723
Webcast: http://public.viavid.com/index.php?id=124321
   
Replays – Available through May 25, 2017
Domestic: 844-512-2921
International: 412-317-6671
Conference ID: 13661723

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.

Contact:
Ohr Pharmaceutical Inc. 
Investor Relations  
888-388-2327   
ir@ohrpharmaceutical.com 

LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvisors.com

Primary Logo

Source: Ohr Pharmaceutical, Inc.